A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Completed · Phase 1 · NCT06132126
Conditions: Healthy, Type 2 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $907,648
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3938577 (drug), Placebo (drug), Insulin degludec (drug)
- Dates
- Started 2023-11-17; completion 2024-06-28
- Results posted
- Not yet
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
From ClinicalTrials.gov, last updated 2024-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $907,648 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amina Z. Haggag, M.D. Family Medicine · Northridge, CA
- Sandra Pagnussat, M.D. Rheumatology · Las Vegas, NV
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $673,262
- Qps-Mra LLC $139,236
- Anaheim Clinical Trials LLC $95,150
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.